image
Healthcare - Medical - Devices - NASDAQ - US
$ 2.538
-1.22 %
$ 44.5 M
Market Cap
-1.91
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one NVNO stock under the worst case scenario is HIDDEN Compared to the current market price of 2.54 USD, enVVeno Medical Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one NVNO stock under the base case scenario is HIDDEN Compared to the current market price of 2.54 USD, enVVeno Medical Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one NVNO stock under the best case scenario is HIDDEN Compared to the current market price of 2.54 USD, enVVeno Medical Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NVNO

image
$4.0$4.0$3.8$3.8$3.6$3.6$3.4$3.4$3.2$3.2$3.0$3.0$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-23.8 M OPERATING INCOME
5.59%
-21.8 M NET INCOME
7.22%
-16.8 M OPERATING CASH FLOW
10.71%
1.34 M INVESTING CASH FLOW
116.97%
13.6 M FINANCING CASH FLOW
-47.12%
812 K REVENUE
0.00%
-6.7 M OPERATING INCOME
-8.57%
-6.23 M NET INCOME
-10.40%
-5.1 M OPERATING CASH FLOW
-19.39%
-11.1 M INVESTING CASH FLOW
-177.75%
0 FINANCING CASH FLOW
0.00%
Balance Sheet enVVeno Medical Corporation
image
Current Assets 43.7 M
Cash & Short-Term Investments 43.2 M
Receivables 0
Other Current Assets 581 K
Non-Current Assets 1.22 M
Long-Term Investments 0
PP&E 1.19 M
Other Non-Current Assets 31 K
95.99 %Total Assets$45.0m
Current Liabilities 2.1 M
Accounts Payable 1.01 M
Short-Term Debt 364 K
Other Current Liabilities 725 K
Non-Current Liabilities 700 K
Long-Term Debt 700 K
Other Non-Current Liabilities 0
35.99 %13.02 %25.94 %25.04 %Total Liabilities$2.8m
EFFICIENCY
Earnings Waterfall enVVeno Medical Corporation
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 23.8 M
Operating Income -23.8 M
Other Expenses -2.01 M
Net Income -21.8 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)000(24m)(24m)2m(22m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-51.75% ROE
-51.75%
-48.54% ROA
-48.54%
-55.12% ROIC
-55.12%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis enVVeno Medical Corporation
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)(18m)(18m)(20m)(20m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -21.8 M
Depreciation & Amortization 528 K
Capital Expenditures -37 K
Stock-Based Compensation 4.14 M
Change in Working Capital 290 K
Others 312 K
Free Cash Flow -16.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets enVVeno Medical Corporation
image
NVNO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership enVVeno Medical Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
331 K USD 5
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22nd at 4:00 PM ET IRVINE, CA / ACCESS Newswire / April 16, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in the Virtual Investor Closing Bell Series on Tuesday, April 22, 2025 at 4:00 PM ET. As part of the event, Mr. accessnewswire.com - 2 weeks ago
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium IRVINE, CA / ACCESS Newswire / March 31, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced its abstract has been accepted for presentation at the Society for Clinical Vascular Surgery (SCVS) 52nd Annual Symposium being held March 29-April 2, 2025 in Austin, TX. As part of the SCVS Symposium, Dr. Cassius Iyad Ochoa Chaar, Associate Professor of Surgery, Yale School of Medicine, Division of Vascular and Endovascular Surgery, Principal Investigator, and lead enroller for the VenoValve U.S. pivotal trial, will present the abstract titled, " Impact of the VenoValve on Patients with Primary and Thrombotic Deep Venous Reflux " on Wednesday, April 2, 2025 beginning at 8:20 AM CT. accessnewswire.com - 1 month ago
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25 Cash Burn of $5.2 million in Q4 remains in line with projected $4-5 million quarterly range Cash and investments on hand are sufficient to fund operations beyond the anticipated regulatory approval of VenoValve and the initiation of the enVVe pivotal trial PMA application for the VenoValve submitted, with FDA decision expected in the second half of 2025 On track for enVVe IDE application submission by mid-2025, pending GLP study results IRVINE, CA / ACCESS Newswire / February 28, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today provided a corporate update and reported financial results for the fourth quarter and year-end of 2024. "Throughout 2024, we executed on our primary objectives - the successful submission of our PMA application for the VenoValve®, and the advancement of enVVe towards its U.S. pivotal trial, both critical milestones for enVVeno Medical," commented Robert Berman, CEO of enVVeno Medical. accessnewswire.com - 2 months ago
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference On-demand video webcast now available here IRVINE, CA / ACCESS Newswire / February 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference .  As part of the event, Robert Berman, Chief Executive Officer of enVVeno, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025. accessnewswire.com - 2 months ago
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators. PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the second half of 2025. accessnewswire.com - 2 months ago
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months. 78% of subjects maintained a clinically meaningful benefit of more than 3 points in rVCSS at 24 months, with an average improvement of 8.2 points among the responder cohort. accessnewswire.com - 2 months ago
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe Successful Completion of All Planned Implants in GLP Study enVVe Delivery System Demonstrates Consistent Performance Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave of implants for shorter-term subjects in its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The successful completion of all planned implants in the GLP study, including both long-term and short-term subjects, completes a critical phase of the study. accesswire.com - 4 months ago
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website Interviews with participating patients from the VenoValve® U.S. Pivotal Trial Webcast replay from with the presenting Primary Investigators Presentation with data from the VenoValve U.S. Pivotal Trial Access the Recap Website Here! IRVINE, CA / ACCESSWIRE / November 27, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the launch of a recap website which highlights the Company's participation at the recently held 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium. accesswire.com - 5 months ago
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain The FDA's approval of VenoValve's PMA has the potential to significantly expand NVNO's portfolio of bioprosthetic solutions. zacks.com - 5 months ago
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium 85% Clinical Meaningful Benefit Responder Rate 7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort 75% Median Reduction in Pain (VAS) 87% Median Ulcer Area Reduction 97% Target Vein Patency Rate Improvement in All Patient Reported Quality-of-Life Indicators Company to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium in New York City. The definitive one-year data supports the application submitted earlier this week by enVVeno Medical seeking pre-market authorization (PMA) from the U.S. Food and Drug Administration (FDA) to market and sell the VenoValve in the U.S. Among the data being presented at VEITH are: Eighty five percent (85%) of the subjects in the VenoValve pivotal study that reached the one-year milestone achieved a clinically meaningful benefit of a three (3) or more point improvement in revised Venous Clinical Severity Score (rVCSS). accesswire.com - 5 months ago
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium Company to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 19, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell the VenoValve in the United States. Four (4) out of five (5) modules that comprise the VenoValve PMA application have been submitted, reviewed and approved by the FDA. accesswire.com - 5 months ago
8. Profile Summary

enVVeno Medical Corporation NVNO

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 44.5 M
Dividend Yield 0.00%
Description enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Contact 70 Doppler, Irvine, CA, 92618 https://www.envveno.com
IPO Date May 31, 2018
Employees 37
Officers Mr. Robert A. Berman Chief Executive Officer & Director Ms. Sandy Prietto Vice President of Marketing Dr. Benedict Broennimann M.D. Chief Medical Officer of Outside of United States Mr. Warren Hancock Co-founder Mr. Craig Thomas Glynn Chief Financial Officer, Treasurer & Secretary Dr. Marc H. Glickman M.D. Senior Vice President & Chief Medical Officer Mr. Andrew Cormack Chief Commercial Officer Dr. Hamed Alavi Ph.D. Senior Vice President & Chief Technology Officer